AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8971427 — intervention group
Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 13
Study 1378145 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0
Study 1378145 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 6502373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 100
Study 6502373 — intervention group
Group type: COMPARATOR
Intervention: Axillary temperature measurement
Number of subjects: 100
Study 30318561 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB)
Number of subjects: 152
Study 30318561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IBPB)
Number of subjects: 152
Study 26079743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) for one month
Number of subjects: 4100
Study 26079743 — intervention group
Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy for one month
Number of subjects: 4100
Study 26079743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy
Number of subjects: 4100
Study 26079743 — intervention group
Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy
Number of subjects: 4100
Study 23643328 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202
Study 23643328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study 23643328 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202
Study 21287409 — intervention group
Group type: COMPARATOR
Intervention: ATRA alone
Number of subjects: 37
Study 21287409 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA switched to As(2)O(3) due to side effects of ATRA
Number of subjects: 37
Study 21287409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ATRA and As(2)O(3)
Number of subjects: 37
Study 19142569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein soy-custard (25 En% protein/carbohydrate/fat)
Number of subjects: 25
Study 19142569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein soy-custard (25 En%)
Number of subjects: 25
Study 19142569 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein soy-custard (10 En%)
Number of subjects: 25
Study 16960167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (17.6 mL/d, 1.8 g 20:5n-3, 3.0 g 22:6n-3, 5.9 g total n-3 fatty acids)
Number of subjects: 26
Study 16960167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 26
Study 16960167 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (17.8 mL/d, 8.5 g 18:2n-6)
Number of subjects: 26
Study 16451475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash with 0.2% chlorhexidine and Anti Discoloration System (ADS)
Number of subjects: 15
Study 16451475 — intervention group
Group type: COMPARATOR
Intervention: Mouthwash with 0.2% chlorhexidine without Anti Discoloration System (ADS)
Number of subjects: 15
Study 11722118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin administration
Number of subjects: 0
Study 11722118 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental, propofol, and nimodipine
Number of subjects: 0
Study 11722118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9930635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FX) 20 mg/day (n=67)
Number of subjects: 142
Study 9930635 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AM) daily dose: 115+/‐39.2mg (n=75)
Number of subjects: 142
Study 9930635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FX)
Number of subjects: 142
Study 9930635 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AM)
Number of subjects: 142
Study 7990071 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture biofeedback (PB)
Number of subjects: 27
Study 2921588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 1.5 mg/70 kg
Number of subjects: 0
Study 2921588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 3.0 mg/70 kg
Number of subjects: 0
Study 2921588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 6.0 mg/70 kg
Number of subjects: 0
Study 2921588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (all doses)
Number of subjects: 0
Study 808231 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (2.5 mg, single dose)
Number of subjects: 12
Study 808231 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (single dose)
Number of subjects: 12
Study 31424177 — intervention group
Group type: EXPERIMENTAL
Intervention: SurE (surfactant without endotracheal tube intubation)
Number of subjects: 350
Study 31424177 — intervention group
Group type: COMPARATOR
Intervention: InSurE technique (intubation surfactant and extubation)
Number of subjects: 350
Study 28240013 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy with biofeedback training
Number of subjects: 13
Study 28240013 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy without biofeedback training (Control)
Number of subjects: 13
Study 25409877 — intervention group
Group type: EXPERIMENTAL
Intervention: Light salt (3 g daily for 4 weeks)
Number of subjects: 35
Study 25409877 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (3 g daily for 4 weeks)
Number of subjects: 35
Study 23585522 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 0
Study 23585522 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens
Number of subjects: 0
Study 21911312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (660nm/15mW/3.8J/cm(2)/spot size 4mm(2))
Number of subjects: 70
Study 21911312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (660nm/5mW/1.3J/cm(2)/spot size 4mm(2))
Number of subjects: 70
Study 19536124 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 15
Study 19536124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16441604 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis platelets
Number of subjects: 22
Study 16441604 — intervention group
Group type: COMPARATOR
Intervention: PRP platelets
Number of subjects: 22
Study 15324525 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 66
Study 10903458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Four-Step Technique (RFST) using a Bair Claw
Number of subjects: 2
Study 10903458 — intervention group
Group type: COMPARATOR
Intervention: Standard open technique
Number of subjects: 2
Study 9269942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 12
Study 9269942 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 12
Study 7683989 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 79
Study 7683989 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 79
Study 3498395 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injection at 15 seconds
Number of subjects: 30
Study 3498395 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injection at 30 seconds
Number of subjects: 30
Study 3498395 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injection at 45 seconds
Number of subjects: 30
Study 3498395 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 29314455 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) ≤112 mmHg
Number of subjects: 28771
Study 29314455 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) 113-120 mmHg
Number of subjects: 28771
Study 29314455 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) >125 mmHg
Number of subjects: 28771
Study 29314455 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) highest quintile
Number of subjects: 28771
Study 27571124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosyte (verbascoside, polyvinylpyrrolidone, sodium hyaluronate), 3 mouthwashes/day for 8 days
Number of subjects: 56
Study 27571124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert water-based solution), 3 mouthwashes/day for 8 days
Number of subjects: 56
Study 25219129 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu + Rehab (warm-reinforcing needling combined with Bobath rehabilitation)
Number of subjects: 60
Study 25219129 — intervention group
Group type: COMPARATOR
Intervention: Rehab (Bobath rehabilitation)
Number of subjects: 60
Study 25219129 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu + Rehab
Number of subjects: 60
Study 25219129 — intervention group
Group type: COMPARATOR
Intervention: Rehab
Number of subjects: 60
Study 23898483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 100 mg/kg orally, pre-treated 10 days before and 5 days after ADR treatment
Number of subjects: 0
Study 23898483 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADR) 20 mg/kg i.p.
Number of subjects: 0
Study 20204604 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cholecalciferol 800 IU + calcium 1,000 mg for 3 years
Number of subjects: 593
Study 20204604 — intervention group
Group type: COMPARATOR
Intervention: Neither supplementation nor placebo
Number of subjects: 593
Study 18568230 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported overdenture (IP)
Number of subjects: 53
Study 18568230 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture (CD)
Number of subjects: 53
Study 16630670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1500 mg/m2 on days 1 and 8 every 3 weeks by standard 30 min intravenous infusion (arm A)
Number of subjects: 121
Study 16630670 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 10 mg/m2/min for 150 min on days 1 and 8 every 3 weeks by intravenous infusion at fixed dose rate (arm B)
Number of subjects: 121
Study 12747194 — intervention group
Group type: EXPERIMENTAL
Intervention: Huang Lian Sheng Mai Yin
Number of subjects: 357
Study 10966698 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 180
Study 10966698 — intervention group
Group type: COMPARATOR
Intervention: Oral iodinated contrast medium
Number of subjects: 180
Study 8991324 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Peer Treatment (RPT)
Number of subjects: 46
Study 8991324 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 7948800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (1 mg/kg loading infusion over 2 hours, followed by 0.15 mg/kg/h for 24 hours, then 80 mg orally every 8 or 12 hours)
Number of subjects: 42
Study 7948800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 42
Study 7948800 — intervention group
Group type: COMPARATOR
Intervention: Control (no sotalol)
Number of subjects: 42
Study 2451883 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAP (bleomycin, cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 45
Study 2451883 — intervention group
Group type: COMPARATOR
Intervention: BP (bleomycin plus cisplatin)
Number of subjects: 45
Study 2451883 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAP
Number of subjects: 45
Study 2451883 — intervention group
Group type: COMPARATOR
Intervention: BP
Number of subjects: 45
Study 29573648 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily
Number of subjects: 69
Study 29573648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 29072016 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion combined with kegel exercise therapy
Number of subjects: 45
Study 29072016 — intervention group
Group type: COMPARATOR
Intervention: Simple kegel exercise therapy
Number of subjects: 45
Study 26253933 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training for 8 weeks
Number of subjects: 28
Study 26253933 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 23916916 — intervention group
Group type: EXPERIMENTAL
Intervention: FITT‐C intervention (telephone-based psychosocial intervention for 6 months)
Number of subjects: 250
Study 23916916 — intervention group
Group type: COMPARATOR
Intervention: Non‐directive telephone support (control group)
Number of subjects: 250
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HDL cholesterol
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (in women)
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher non-HDL cholesterol
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HDL cholesterol
Number of subjects: 1266
Study 21247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of diastolic pressure and BMI
Number of subjects: 1266
Study 18165850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb761) 120 mg twice per day
Number of subjects: 0
Study 18165850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16933459 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled gum chewing exercise protocol for eight weeks
Number of subjects: 20
Study 16933459 — intervention group
Group type: COMPARATOR
Intervention: Support and encouragement
Number of subjects: 20
Study 12928941 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®) as monotherapy or in combination with methotrexate
Number of subjects: 0
Study 12928941 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®)
Number of subjects: 0
Study 12928941 — intervention group
Group type: COMPARATOR
Intervention: Anakinra (Kineret®) combined with anti-TNF agents
Number of subjects: 0
Study 11118091 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir prophylaxis
Number of subjects: 0
Study 11118091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2113258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyclonine hydrochloride 1.0% (Dyclone)
Number of subjects: 18
Study 2113258 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous lidocaine with 1% cocaine
Number of subjects: 18
Study 2113258 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin-pectin solution, diphenhydramine plus saline (KBS)
Number of subjects: 18
Study 2113258 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study 483371 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment in addition to a standard regime
Number of subjects: 52
Study 483371 — intervention group
Group type: COMPARATOR
Intervention: Standard regime without steroids
Number of subjects: 52
Study 31992219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-based gait rehabilitation program
Number of subjects: 40
Study 31992219 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy care
Number of subjects: 40
Study 31149999 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral analgesia
Number of subjects: 40
Study 31149999 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 40
Study 28547735 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 2385
Study 28547735 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable Medication-Overuse Headache (pMOH)
Number of subjects: 2385
Study 28547735 — intervention group
Group type: EXPERIMENTAL
Intervention: Any headache yesterday (HY)
Number of subjects: 2385
Study 28547735 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall headache disability
Number of subjects: 2385
Study 26033941 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised cognitive functional therapy (CFT)
Number of subjects: 214
Study 26033941 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise and pain education class
Number of subjects: 214
Study 23548162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 872
Study 23548162 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (non-specific general information about the role of stress in heart disease)
Number of subjects: 872
Study 21898340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 800 mg once daily for 6 months
Number of subjects: 162
Study 21898340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 19573383 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone solution (Iintropin AQ)
Number of subjects: 31
Study 16706763 — intervention group
Group type: EXPERIMENTAL
Intervention: ClozeX
Number of subjects: 15
Study 16706763 — intervention group
Group type: COMPARATOR
Intervention: suture
Number of subjects: 15
Study 14716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on osteoporosis
Number of subjects: 195
Study 14716192 — intervention group
Group type: COMPARATOR
Intervention: Routine physician visit (control)
Number of subjects: 195
Study 11466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-obesity surgery
Number of subjects: 0
Study 11466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative patient education
Number of subjects: 0
Study 11466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 11466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient knowledge, psychosocial adaptation, and motivational factors
Number of subjects: 0
Study 11466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life after bariatric surgery
Number of subjects: 0
Study 11466602 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged approach to bariatric surgery
Number of subjects: 0
Study 9040450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 50 mg losartan and 10 mg enalapril
Number of subjects: 12
Study 9040450 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 12
Study 9040450 — intervention group
Group type: COMPARATOR
Intervention: 20 mg enalapril
Number of subjects: 12
Study 7738214 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/m2/hr DDTC
Number of subjects: 15
Study 7738214 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/m2/hr DDTC
Number of subjects: 15
Study 3189700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous crystalline penicillin for 5 days
Number of subjects: 79
Study 3189700 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids only (Control)
Number of subjects: 79
Study 30894162 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Number of subjects: 76
Study 30894162 — intervention group
Group type: COMPARATOR
Intervention: Lecture (traditional lecture-style education)
Number of subjects: 76
Study 30894162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (simulation and lecture)
Number of subjects: 76
Study 28640017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 64
Study 28640017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 64
Study 28640017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 64
Study 28640017 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 64
Study 28640017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of reparalysis
Number of subjects: 64
Study 25530111 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride (0.5 mg, three times daily)
Number of subjects: 67
Study 25530111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 24179976 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (test group)
Number of subjects: 80
Study 24179976 — intervention group
Group type: COMPARATOR
Intervention: Early loading (control group)
Number of subjects: 80
Study 22008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg intravenously) + 0.25% ropivacaine (2 mL per incision, 6 mL total)
Number of subjects: 80
Study 22008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg intravenously) + 0.5% ropivacaine (2 mL per incision, 6 mL total)
Number of subjects: 80
Study 22008690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesics administered)
Number of subjects: 80
Study 19691368 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA(t) concentrations
Number of subjects: 88
Study 19691368 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in CL(CR) from 60 to 25 mL/min
Number of subjects: 88
Study 19691368 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulation of MPAG(t) concentrations from 50 to 150 mg/L
Number of subjects: 88
Study 19691368 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in plasma albumin concentration from 40 to 30 g/L
Number of subjects: 88
Study 19691368 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA(u) clearance
Number of subjects: 88
Study 17005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 10 mg/kg once daily for 14 days
Number of subjects: 36
Study 17005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 12 mg/kg once daily for 14 days
Number of subjects: 36
Study 17005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 or 8 mg/kg once daily for 4 days
Number of subjects: 36
Study 17005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (various doses)
Number of subjects: 36
Study 17005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin up to 12 mg/kg intravenously for 14 days
Number of subjects: 36
Study 17005801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14533665 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microg twice daily
Number of subjects: 22